Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 399-407

  Deforche, Koen ^a   Cozzi Lepri, Alessandro ^a   Theys, Kristof ^a   Clotet, Bonaventura ^c   Camacho, Ricardo J ^d   Kjaer, Jesper ^e   Van Laethem, Kristel ^a   Phillips, Andrew ^b   Moreau, Yves ^a   Lundgren, Jens D ^e,f   Vandamme, Anne Mieke ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Centro Hospitalar de Lisboa Ocidental   (Portugal)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC MODEL; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; RISK; STATISTICAL SIGNIFICANCE; TIME; TREATMENT RESPONSE; VIRAL GENETICS; VIROLOGY; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MUTATION; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MUTATION; NELFINAVIR; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 47249117584     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Vandamme AM. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 1999; 57:337-361.
2. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9:829-848.
3. DiRienzo G, DeGruttola V. Collaborative HIV resistance-response database initiatives: sample size for detection of relationships between HIV-1 genotype and HIV-1 RNA response using a non-parametric approach. Antivir Ther 2002; 7:S71.
4. Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49:1739-1744.
5. Van Laethem K, Vandamme AM. Interpreting resistance data for HIV-1 therapy management - know the limitations. AIDS Reviews 2006; 8:37-43.
6. Deforche K, Camacho R, Van Laethem K, et al. Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 2007; 24:34-41.
7. Snoeck J, Kantor R, Shafer RW, et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006; 50:694-701.
8. de Oliveira T, Deforche K, Cassol S, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800.
9. Deforche K, Silander T, Camacho R, et al. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics 2006; 22:2975-2979.
10. Beerenwinkel N, Rahnenführer J, Däumer M, et al. Learning multiple evolutionary pathways from cross-sectional data. J Compu Biol 2005; 12:584-598.
11. Beerenwinkel N, Daumer M, Oette M, et al. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucl Acids Res 2003; 31:3850-3855.
12. Wang D, Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 2003; 188:653-660.
13. Loutfy MR, Raboud JM, Walmsley SL, et al. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Antivir Ther 2004; 9:595-602.
14. Larder B, Wang D, Revell A, et al. The development of artificial neuralnetworks to predict virological response to combination HIV therapy. Antivir Ther 2007; 12:15-24.
15. Altmann A, Beerenwinkel N, Sing T, et al. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther 2007; 12:169-178.
16. De Luca A, Cingolani A, Giambenedetto SD, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187:1934-1943.
17. Fox ZV, Geretti AM, Kjaer J, et al. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS 2007; 21:2033-2042.
18. Roquebert B, Malet I, Wirden M, et al. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors. AIDS 2006; 20:287-289.
19. Fardet L, Mary-Krause M, Heard I, et al. On HIV FHD, influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response. HIV Med 2006; 7:520-529.
20. Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-I. J Clin Virol 2004; 29:152-159.
21. Osmanov S, Pattout C, Walker N, et al. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquit Immune Defic Syndr 2002; 29:184-190.
22. Böni J, Pyra H, Gebhardt M, et al. High frequency of non-B-subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr 1999; 22:174-179.
23. Balotta C, Facchi G, Violin M, et al. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr 2001; 27:499-505.
24. Snoeck J, Laethem KV, Hermans P, et al. Rising prevalence of HIV-1 non-B -subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr 2004; 35:279-285.
25. Aggarwal I, Smith M, Tatt ID, et al. Evidence for onward transmission of HIV-1 -subtype strains in the United Kingdom. J Acquir Immune Defic Syndr 2006; 41:201-209.